WallStreetZenWallStreetZen

NYSE: BIO
Bio Rad Laboratories Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Bio Rad Laboratories earnings were $222.4M for the trailing 12 months ending Jun 30, 2026, with -32.1% growth year over year. The latest BIO earnings report on Jun 30, 2026 announced Q2 2026 earnings of $371.4M, down 170.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, BIO reported annual earnings of $759.9M, with -141.2% growth.

BIO past earnings growth

How has BIO's earnings growth performed historically?

Company
-32.12%
Industry
-3.28%
Market
93.82%
BIO's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
BIO's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
BIO's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

BIO earnings history

Current Revenue
$2.6B
Current Earnings
$222.4M
Current Profit Margin
8.6%
BIO's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

BIO Return on Equity

Current Company
3.2%
Current Industry
-6.9%
Current Market
31.1%
BIO's Return on Equity (3.2%)... subscribe to Premium to read more.
High Return on Equity Performance

BIO Return on Assets

Current Company
2.2%
Current Industry
5.3%
BIO is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when BIO announces earnings.

BIO Return on Capital Employed

Current Company
4.3%
Current Industry
9.6%
BIO has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BIO vs Medical Device Stocks

TickerEBITDAEarningsY/Y EarningsEPS
BIO$399.20M$222.40M-43.19%$8.05
GMED$922.34M$535.43M+16.50%$3.97
PODD$652.60M$375.30M+79.97%$5.35
GKOS-$141.49M-$188.05MN/A-$3.26
ALGN$864.22M$413.58M-8.23%$5.76
View Top Medical Device Stocks

Bio Rad Laboratories Earnings Reports & History FAQ

What were Bio Rad Laboratories's earnings last quarter?

On BIO's earnings call on Aug 4, 2026, Bio Rad Laboratories (NYSE: BIO) reported Q2 2026 earnings per share (EPS) of $13.89, up 19.02% year over year. Total BIO earnings for the quarter were $371.40 million. In the same quarter last year, Bio Rad Laboratories's earnings per share (EPS) was $11.67.

If you're new to stock investing, here's how to buy Bio Rad Laboratories stock.

Is Bio Rad Laboratories profitable or losing money?

As of the last Bio Rad Laboratories earnings report, Bio Rad Laboratories is currently profitable. Bio Rad Laboratories's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $222.40 million, a 30.33% decrease year over year.

What was BIO's earnings growth in the past year?

As of Bio Rad Laboratories's earnings date in Aug 4, 2026, Bio Rad Laboratories's earnings has grown -32.12% year over year. This is 28.84 percentage points lower than the US Medical Devices industry earnings growth rate of -3.28%. BIO earnings in the past year totalled $222.40 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.